183550-71-2

Upstream product

• 183550-77-8 diethyl 5,6-dihydro-5-hydroxy-5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6,6-dicarboxylate 
• 183550-78-9 5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxylic acid 
• 508210-17-1 8-Oxo-5-p-tolyl-8H-pyrano[3,4-b]pyridine-6-carbonyl chloride 
• 508210-05-7 3-p-toluoyl-pyridine-2-carbonyl chloride 
• 116060-91-4 3-(4-methylbenzoyl)-2-pyridine carboxylic acid 
• 141-43-5 ethanolamine 
• 183550-80-3 N-[3,5-bis(trifluoromethyl)benzyl]-5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxamide 

Downstream Products

• 244107-37-7 N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-7-(2-methanesulfonyloxyethyl)-5-(4-methylphenyl)-8-oxo-6-pyrido[3,4-b]pyridine carboxamide 
• 183145-60-0 7-[3,5-Bis(trifluoromethyl)benzyl]-6,7,8,9-tetrahydro-5-(4-methylphenyl)-6,11-dioxo-11H-pyrazino[2,1-g][1,7]naphthyridine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE

A compound represented by the formula: wherein ring M is a heterocyclic ring wherein--X=Yis one of--N=C,--CO--N or--CS--N; Ra and Rb are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, with the proviso that at least one of them is an optionally substituted heterocyclic ring; Ring C is an optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted nitrogen-containing heterocyclic ring; and n is an integer from 1 to 6, or a salt thereof has a tachykinin receptor antagonistic activity in vitro, and is useful for preventing or treating depression, anxiety, manic-depressive illness or psychopathy.

Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK1 receptor antagonists: Synthesis, antagonistic activity, and effects on bladder functions

Cyclic analogues of N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-N,7- dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide (1) having a 6-9-membered ring (6-9) were synthesized and evaluated for NK1 antagonistic activities. The 8

CYCLIC COMPOUNDS, THEIR PRODUCTION AND USE

Novel compounds of the following general formula or salts thereof. STR1 wherein Ring M is a heterocyclic ring having--N=C ,--CO--N or--CS--N as the partial structure--X . . . Y ; R. sup.a and R. sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Rng C is optionally substituted homocyclic or heterocyclic ring; Rng Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has anexcellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.